标题
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-09-21
DOI
10.3389/fonc.2022.973836
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
- (2022) Elina Alaterre et al. Theranostics
- The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
- (2022) Antonio Giovanni Solimando et al. Cancers
- Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
- (2021) Kazuhito Suzuki et al. Cancers
- Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
- (2021) Samuel S. McCachren et al. Frontiers in Immunology
- Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
- (2021) Vanessa Innao et al. Cells
- Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
- (2021) Esperanza M. Algarín et al. Cells
- G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death
- (2021) Eva De Smedt et al. Blood Advances
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)
- (2021) Dante Pennipede et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
- (2021) Madelon M. E. de Jong et al. NATURE IMMUNOLOGY
- Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
- (2021) Laurie Herviou et al. Clinical Epigenetics
- MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
- (2021) Vanessa Desantis et al. Cancers
- The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
- (2021) Domenico Ribatti et al. Cancers
- Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
- (2021) Mary Slavcev et al. ClinicoEconomics and Outcomes Research
- Junctional Adhesion Molecule-C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans
- (2021) Andreas Brandl et al. Blood Advances
- Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival
- (2020) Antonio Giovanni Solimando et al. BLOOD
- Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2020) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Immune system and bone microenvironment: rationale for targeted cancer therapies
- (2020) Gnoni Antonio et al. Oncotarget
- Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
- (2020) Giuseppe Di Lernia et al. Journal of Clinical Medicine
- miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro
- (2020) Markus Krebs et al. Journal of Clinical Medicine
- HB-EGF–EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma
- (2020) Luigia Rao et al. Cancers
- Multiple Myeloma: Available Therapies and Causes of Drug Resistance
- (2020) Vanessa Pinto et al. Cancers
- Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma
- (2020) Stefania Raimondo et al. Cancers
- Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression.
- (2020) Antonio G. Solimando et al. HAEMATOLOGICA
- MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
- (2020) Vanessa Desantis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
- (2020) Carolane Seiller et al. Cell Death & Disease
- Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
- (2020) Antonella Argentiero et al. Journal of Clinical Medicine
- A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
- (2020) Antonio Giovanni Solimando et al. Journal of Oncology
- Hypoxia‐inducible hexokinase‐2 enhances anti‐apoptotic function via activating autophagy in multiple myeloma
- (2020) Sho Ikeda et al. CANCER SCIENCE
- Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
- (2020) Matthew Ho et al. Clinical Lymphoma Myeloma & Leukemia
- Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
- (2020) Cesarina Giallongo et al. Cancers
- Tissue-resident memory-like T cells in tumor immunity: Clinical implications
- (2020) Madhav V. Dhodapkar et al. SEMINARS IN IMMUNOLOGY
- Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
- (2020) Nicholas Theodoropoulos et al. Targeted Oncology
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
- (2020) Antonio Giovanni Solimando et al. Cancers
- Exosome-Transmitted PSMA3 and PSMA3-AS1 Promotes Proteasome Inhibitors Resistance in Multiple Myeloma
- (2019) Hongxia Xu et al. CLINICAL CANCER RESEARCH
- Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
- (2019) Danielle Harmer et al. Frontiers in Endocrinology
- Metabolic, anti-apoptotic and immune evasion strategies of primary human myeloma cells indicate adaptations to hypoxia
- (2019) Lukas Janker et al. MOLECULAR & CELLULAR PROTEOMICS
- An HK2 antisense oligonucleotide induces synthetic lethality in HK1-HK2+ multiple myeloma
- (2019) Shili Xu et al. CANCER RESEARCH
- High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
- (2019) Antonio Giovanni Solimando et al. Journal of Clinical Medicine
- IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma
- (2019) Santiago Barrio et al. HAEMATOLOGICA
- Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
- (2019) Antonella Argentiero et al. Cancers
- Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
- (2019) Chad C. Bjorklund et al. LEUKEMIA
- CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement
- (2019) Matteo Claudio Da Vià et al. ONCOLOGIST
- Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs
- (2019) Patrizia Leone et al. Journal of Clinical Medicine
- The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
- (2019) Sylvia Faict et al. Cancers
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma
- (2018) Vanessa Desantis et al. ANNALS OF HEMATOLOGY
- PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy
- (2018) Alessandra Romano et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior
- (2018) Shyam K. Bandari et al. MATRIX BIOLOGY
- The multiple myelomas — current concepts in cytogenetic classification and therapy
- (2018) Shaji K. Kumar et al. Nature Reviews Clinical Oncology
- Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis
- (2018) Bingzong Li et al. ONCOGENE
- Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
- (2018) Aurelia Lamanuzzi et al. Oncotarget
- Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study
- (2018) Luigia Rao et al. Oncotarget
- Targeting Bcl-2 for the treatment of multiple myeloma
- (2018) Cyrille Touzeau et al. LEUKEMIA
- BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
- (2018) Patricia Gomez-Bougie et al. BLOOD
- The ERK and JNK pathways in the regulation of metabolic reprogramming
- (2018) Salvatore Papa et al. ONCOGENE
- PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
- (2018) Laurie Herviou et al. Clinical Epigenetics
- Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients
- (2018) Patrizia Leone et al. OncoImmunology
- Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
- (2017) Ana-Alicia López-Iglesias et al. Journal of Hematology & Oncology
- JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
- (2017) A G Solimando et al. LEUKEMIA
- Melflufen - a peptidase-potentiated alkylating agent in clinical trials
- (2017) Malin Wickström et al. Oncotarget
- Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a
- (2017) Qian Cheng et al. Stem Cells International
- Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage
- (2017) Andrew J. Massey Scientific Reports
- Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
- (2016) M. S. Raab et al. BLOOD
- The effects of proteasome inhibitors on bone remodeling in multiple myeloma
- (2016) Maurizio Zangari et al. BONE
- A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
- (2016) Arghya Ray et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo
- (2016) Vidal Jarauta et al. CANCER LETTERS
- Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity
- (2016) Kim De Veirman et al. CANCER LETTERS
- Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
- (2016) Yusuke Furukawa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
- (2016) Jinheng Wang et al. JOURNAL OF PATHOLOGY
- Targeting B-cell non Hodgkin lymphoma: New and old tricks
- (2016) Antonio Giovanni Solimando et al. LEUKEMIA RESEARCH
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Histone deacetylase inhibitors as immunomodulators in cancer therapeutics
- (2016) Li Shen et al. Epigenomics
- Multiple myeloma cancer stem cells
- (2016) Minjie Gao et al. Oncotarget
- Microenvironment drug resistance in multiple myeloma: emerging new players
- (2016) Lucia Di Marzo et al. Oncotarget
- Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
- (2016) Cesarina Giallongo et al. Oncotarget
- Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
- (2015) P. Maiso et al. CANCER RESEARCH
- Molecular mechanisms in multiple myeloma drug resistance
- (2015) Nicholas Nikesitch et al. JOURNAL OF CLINICAL PATHOLOGY
- Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
- (2015) C C Bjorklund et al. Blood Cancer Journal
- Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation
- (2015) Zhiqiang Liu et al. Oncotarget
- GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells
- (2015) Alboukadel Kassambara et al. PLoS Computational Biology
- Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
- (2015) Wen-Chi Yang et al. Biomed Research International
- In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
- (2015) Maria Teresa Di Martino et al. Oncotarget
- Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
- (2015) Xenofon Papanikolaou et al. Oncotarget
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Combined autophagy and proteasome inhibition
- (2014) Dan T Vogl et al. Autophagy
- Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
- (2014) J. Wang et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1
- (2014) T. Umezu et al. BLOOD
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
- (2014) A. Ferrucci et al. CLINICAL CANCER RESEARCH
- Targeting the bone marrow microenvironment in multiple myeloma
- (2014) Yawara Kawano et al. IMMUNOLOGICAL REVIEWS
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- microRNAs in cancer stem cells: current status and future directions
- (2014) Ravindresh Chhabra et al. TUMOR BIOLOGY
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
- (2013) Robert Z. Orlowski CANCER CELL
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
- (2013) Wen Zhou et al. CANCER CELL
- DNA repair pathways in human multiple myeloma
- (2013) Claire Gourzones-Dmitriev et al. CELL CYCLE
- Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
- (2013) M. Moschetta et al. CLINICAL CANCER RESEARCH
- Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells
- (2013) I.S. Song et al. INTERNATIONAL JOURNAL OF CANCER
- BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
- (2013) Aldo M. Roccaro et al. JOURNAL OF CLINICAL INVESTIGATION
- A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
- (2013) M F Kaiser et al. LEUKEMIA
- ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma
- (2013) W Zhou et al. LEUKEMIA
- Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
- (2013) L. Vincenz et al. MOLECULAR CANCER THERAPEUTICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- Targeting the BRAF V600E Mutation in Multiple Myeloma
- (2013) M. Andrulis et al. Cancer Discovery
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- (2012) N G Gavalas et al. BRITISH JOURNAL OF CANCER
- Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
- (2012) K. Boucher et al. CLINICAL CANCER RESEARCH
- Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
- (2012) J. Hu et al. Disease Models & Mechanisms
- Primary Mesenchymal Stem and Progenitor Cells from Bone Marrow Lack Expression of CD44 Protein
- (2012) Hong Qian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Arsenic Trioxide Exerts Antimyeloma Effects by Inhibiting Activity in the Cytoplasmic Substrates of Histone Deacetylase 6
- (2012) Xiaoyan Qu et al. PLoS One
- Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
- (2012) T Ishii et al. Blood Cancer Journal
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
- (2011) J. Jakubikova et al. HAEMATOLOGICA
- Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma
- (2011) Masahiro Abe INTERNATIONAL JOURNAL OF HEMATOLOGY
- Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
- (2011) T. Khong et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
- (2010) J. Moreaux et al. BLOOD
- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
- (2010) B. A. Walker et al. BLOOD
- Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways
- (2010) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
- (2010) J. E. Bohonowych et al. Journal of Oncology
- The potential role of epigenetic therapy in multiple myeloma
- (2009) Emma M. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- Arginase: an emerging key player in the mammalian immune system
- (2009) Markus Munder BRITISH JOURNAL OF PHARMACOLOGY
- The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
- (2009) M. Milani et al. CANCER RESEARCH
- EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
- (2009) Milena Sant et al. EUROPEAN JOURNAL OF CANCER
- Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors
- (2009) M Garayoa et al. LEUKEMIA
- Cancer stem cells in multiple myeloma
- (2008) Nilanjan Ghosh et al. CANCER LETTERS
- Emerging role of Notch in stem cells and cancer
- (2008) Zhiwei Wang et al. CANCER LETTERS
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search